HeartSciences Inc. (HSCS) Dividend History

HeartSciences Inc. (HSCS) develops and commercializes non-invasive cardiac monitoring and diagnostic solutions. The company's technology aims to improve detection and management of cardiac conditions through innovative, portable, and easy-to-use devices that support early diagnosis and better patient outcomes.

550 Reserve St, Suite 360, Southlake, TX, 76092
Phone: 682-237-7781
Website:

Dividend History

HeartSciences Inc. currently does not pay dividends

Company News

  • HeartSciences Signs First MyoVista Insights™ Platform Customer, Marking Major Commercial Milestone

    HeartSciences, an AI-powered medical technology company, announced its first commercial customer for the MyoVista Insights platform, Westcliffe Health Innovations in the U.K. This partnership aims to enhance ECG management and improve healthcare efficiency.

    GlobeNewswire Inc.
  • HeartSciences Announces Launch of MyoVista Insights™ Platform and Related Early Adopter Program

    HeartSciences, an AI-powered medical technology company, has launched the MyoVista Insights platform, a cloud-native ECG management system designed to enhance clinical decision-making and healthcare IT efficiency. The platform features AI-ECG algorithms, streamlined workflows, and advanced cybersecurity.

    GlobeNewswire Inc.
  • HeartSciences Regains Compliance with Nasdaq Listing Requirements

    Southlake, TX, June 04, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced that on June 3, 2024, the Company received formal notice from the Listing Qualifications Staff of the Nasdaq Stock Market LLC indicating that HeartSciences has regained compliance with bid price requirement as set forth in Listing Rule 5550(a)(2), and that the Company is therefore in compliance with the Nasdaq Capital Market’s listing requirements and the scheduled hearing has now been cancelled.

    GlobeNewswire Inc.
  • HeartSciences to Present at the LD Micro Invitational XIV Conference

    Southlake, TX, April 02, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences  (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced that Chief Executive Officer Andrew Simpson is scheduled to present at the LD Micro Invitational XIV Conference on Tuesday April 9, 2024 at 5:00pm ET at the Sofitel New York. Mr. Simpson will also be hosting one-on-one meetings through the conference.

    GlobeNewswire Inc.
  • HeartSciences Reports Third Quarter Fiscal 2024 Financial Results

    Southlake, TX, March 14, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today reported financial results for the third quarter fiscal 2024 ended January 31, 2024 and provided a business update.

    GlobeNewswire Inc.
Dividend data last updated 06/07/2025 20:09:57 UTC